Overcoming Endocrine Resistance in Metastatic Breast Cancer

NCT02394496 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

396

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Fulvestrant
DRUG: Lapatinib
DRUG: Aromatase Inhibitors
DRUG: Placebo Lapatinib

Sponsor

Consorzio Oncotech